FEATURED EDITORIAL
Beyond Australia: Why Medtech Startups Are Re-Evaluating FIH Trial Destinations
The advice handed to medtech companies planning a first-in-human (FIH) study has been: go to Australia. That advice is now overdue for a rewrite. Not because Australia stopped working, but because the math changed.
-
Where can digital technologies can solve real problems for patients, healthcare providers, and industry, while avoiding unnecessary complexity? Here's where the strongest value propositions currently sit.
-
P-tau217 blood tests could accelerate Alzheimer’s diagnosis. Lilly’s Nino Sireci, MD, MSc, explains the research, evidence thus far, potential clinical use, and next steps.
-
The European Commission's simplification package is being debated almost entirely as an MDR story. The IVDR provisions carry the same legal force, and the window to shape them closes this fall.
INDUSTRY INSIGHTS
-
The PMCF Decision Guide
Proposed EU reforms may remove standalone PMCF reporting, yet the duty to proactively collect clinical data remains. Method selection, notified body defense, and data-capture cost determine what comes next.
Removing the handoff between patient self-screening and enrollment changes what a fully virtual observational study can achieve, from conversion at peak intent to completion rates among participants.
Pharma can’t simply eliminate essential PFAS uses. A phased, risk-based strategy can address footprint, exposure, and supply risks amid regulatory uncertainty.
Regulators now separate fluoropolymers from other PFAS, but lifecycle risks remain. Readiness starts with knowing which uses, reporting duties, and exposures matter most.
Replacing fluorinated chemistries across pharma isn’t simple. Growing pressures make it critical to prioritize risks and take a sequenced, evidence-based approach to mitigation.
MED DEVICE ONLINE CONTENT COLLECTIONS
Artificial Intelligence and Machine Learning are taking the life sciences world by storm. Do you know how to harness its power for your medical device? Check out our latest e-book which examines the opportunities AI and ML offer to both complement and supplement human intelligence in the medical device industry.
More Content CollectionsLATEST HEADLINES
- Nordson MEDICAL Introduces The New Divert™ ULTRA Line Of Ultra-High- Pressure Stopcocks For Demanding Medical Applications
- Curi Bio And Battelle Announce Strategic Partnership To Accelerate The Adoption Of NAMs In Neuromuscular Pharmacology
- NeuroLife® Launch Brings Non-Invasive Technology Aimed At Restoring Hand And Arm Movement After Stroke And Spinal Cord Injury
- Discover Medbio's Advanced Manufacturing Solutions For Injectable & Drug Delivery Device
- Discover Medbio's Advanced Manufacturing Expertise for Robot-Assisted Surgery At DeviceTalks Boston 2026
- Discover Medbio's End-to-End Medical Manufacturing Expertise & Scalability At INTERPHEX 2026
- Lifecore Biomedical Signs New Agreement With Indomo To Support Innovative Drug/Device Combination Acne Treatment
- Strategy Beyond The Bench: Eurofins Launches New U.S. Consulting Chapter In Medtech Strategy & Policy